These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 8301153)

  • 21. Nursing management of MS patients receiving interferon beta-1b therapy.
    Costello K; Conway K
    Rehabil Nurs; 1997; 22(2):62-6, 81. PubMed ID: 9110845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advancing treatment with interferon beta-1b (Betaferon/Betaseron) in the next decade--thinking beyond the standard dose.
    Cook SD
    J Neurol; 2003 Dec; 250 Suppl 4():IV15-20. PubMed ID: 14712397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study.
    Patti F; Morra VB; Amato MP; Trojano M; Bastianello S; Tola MR; Cottone S; Plant A; Picconi O;
    PLoS One; 2013; 8(8):e74111. PubMed ID: 24137499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-beta1a.
    Antonelli G; Bagnato F; Pozzilli C; Simeoni E; Bastianelli S; Currenti M; De Pisa F; Fieschi C; Gasperini C; Salvetti M; Dianzani F
    J Interferon Cytokine Res; 1998 May; 18(5):345-50. PubMed ID: 9620362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of subcutaneous interferon β-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study.
    De Stefano N; Sormani MP; Stubinski B; Blevins G; Drulovic JS; Issard D; Shotekov P; Gasperini C
    J Neurol Sci; 2012 Jan; 312(1-2):97-101. PubMed ID: 21880336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term interferon-beta treatment for multiple sclerosis.
    Ruggieri RM; Settipani N; Viviano L; Attanasio M; Giglia L; Almasio P; La Bella V; Piccoli F
    Neurol Sci; 2003 Dec; 24(5):361-4. PubMed ID: 14716534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An open-labelled assessment of adverse effects associated with interferon 1-beta in the treatment of multiple sclerosis.
    Logan-Clubb L; Stacy M
    J Neurosci Nurs; 1995 Dec; 27(6):344-7. PubMed ID: 8770778
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
    Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recurrent injection site reactions from interferon beta 1-b.
    Samuel L; Lowenstein EJ
    J Drugs Dermatol; 2006 Apr; 5(4):366-7. PubMed ID: 16673806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence of exacerbations in the first 90 days of treatment with recombinant human interferon beta-1b in patients with relapsing-remitting multiple sclerosis.
    Khan OA; Hebel JR
    Ann Neurol; 1998 Jul; 44(1):138-9. PubMed ID: 9667604
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
    Patti F; Amato MP; Bastianello S; Caniatti L; Di Monte E; Ferrazza P; Goretti B; Gallo P; Morra VB; Lo Fermo S; Picconi O; Tola MR; Trojano M;
    Mult Scler; 2010 Jan; 16(1):68-77. PubMed ID: 19995846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of interferon β-1a and interferon β-1b monotherapies on selected serum cytokines and nitrite levels in patients with relapsing-remitting multiple sclerosis: a 3-year longitudinal study.
    Stępień A; Chalimoniuk M; Lubina-Dąbrowska N; Chrapusta SJ; Galbo H; Langfort J
    Neuroimmunomodulation; 2013; 20(4):213-22. PubMed ID: 23711618
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Therapy of multiple sclerosis with interferon-beta-1b. Educating the patient and managing side-effects].
    Walther EU; Dietrich E; Hohlfeld R
    Nervenarzt; 1996 Jun; 67(6):452-6. PubMed ID: 8767199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
    Kappos L; Li D; Calabresi PA; O'Connor P; Bar-Or A; Barkhof F; Yin M; Leppert D; Glanzman R; Tinbergen J; Hauser SL
    Lancet; 2011 Nov; 378(9805):1779-87. PubMed ID: 22047971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lessons from 10 years of interferon beta-1b (Betaferon/Betaseron) treatment.
    Bayas A; Gold R
    J Neurol; 2003 Dec; 250 Suppl 4():IV3-8. PubMed ID: 14712395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The quality-of-life effects of interferon beta-1b in multiple sclerosis. An extended Q-TWiST analysis.
    Schwartz CE; Coulthard-Morris L; Cole B; Vollmer T
    Arch Neurol; 1997 Dec; 54(12):1475-80. PubMed ID: 9400356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term benefits of early and high doses of interferon beta-1a treatment in relapsing-remitting multiple sclerosis.
    Chofflon M; Ben-Amor AF
    Clin Neurol Neurosurg; 2002 Jul; 104(3):244-8. PubMed ID: 12127662
    [No Abstract]   [Full Text] [Related]  

  • 38. PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis.
    Baker DP; Pepinsky RB; Brickelmaier M; Gronke RS; Hu X; Olivier K; Lerner M; Miller L; Crossman M; Nestorov I; Subramanyam M; Hitchman S; Glick G; Richman S; Liu S; Zhu Y; Panzara MA; Davar G
    J Interferon Cytokine Res; 2010 Oct; 30(10):777-85. PubMed ID: 20836711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration.
    Khan OA; Xia Q; Bever CT; Johnson KP; Panitch HS; Dhib-Jalbut SS
    Neurology; 1996 Jun; 46(6):1639-43. PubMed ID: 8649563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is multiple sclerosis a disease that requires frequent beta interferon dosing?
    Durelli L
    J Neurol; 2004 Sep; 251 Suppl 4():IV13-24. PubMed ID: 15378303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.